DXCM240802C108000
- 0.02
- 0.000.00%
DexCom Newsroom
Raymond James Maintains DexCom(DXCM.US) With Buy Rating, Cuts Target Price to $115
Redburn Atlantic Adjusts Price Target on DexCom to $80 From $130
Dexcom's Stock Downgrade: A Temporary Setback or a Buying Opportunity?
DexCom Analyst Ratings
Dexcom's Strong Market Position and Growth Potential Affirm Buy Rating Despite Initial Rebate Confusion
Barclays Maintains DexCom(DXCM.US) With Hold Rating, Maintains Target Price $113
Analysts' Opinions Are Mixed on These Healthcare Stocks: MacroGenics (MGNX) and Dexcom (DXCM)
DexCom Price Target Cut to $75.00/Share From $120.00 by Morgan Stanley
BTIG Maintains DexCom(DXCM.US) With Buy Rating, Cuts Target Price to $120
Oppenheimer Maintains DexCom(DXCM.US) With Buy Rating, Cuts Target Price to $115
RBC Capital Maintains DexCom(DXCM.US) With Buy Rating, Cuts Target Price to $145
Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), Tenaya Therapeutics (TNYA) and Cue Biopharma (CUE)
DexCom Analyst Ratings
Dexcom (DXCM) Gets a Buy From RBC Capital
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ovid Therapeutics (OVID) and Dexcom (DXCM)
Raymond James Adjusts Price Target on DexCom to $115 From $160
Dexcom: A Cautious Hold Amid Competitive Challenges and Operational Headwinds
CCORF Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $145
DexCom Analyst Ratings
Dexcom's Market Leadership and Strategic Growth Opportunities Affirm Buy Rating